Polymyalgia rheumatica and exercise

What the research found.

• At the first visit, 71.2 percent of these patients were already heading toward frailty, against 34.4 percent in the controls. That works out at an odds ratio of 4.7 for the patient group. At follow-up, which came nearly two years after treatment began, it was still 60.7 percent.

  Leung and colleagues, Rheumatology, 2025

• Women with polymyalgia rheumatica slowed down more when walking than female controls did, by 0.13 meters per second. They were also 3.27 seconds slower getting out of a chair. Both of those measure everyday function rather than pain or blood markers, which is what makes the difference worth watching.

  Leung and colleagues, Rheumatology, 2025

• Bad tiredness hit 36 percent of patients at the start and 35 percent at follow-up, against 3 percent in the controls. Poor sleep hit 77 percent and then 84 percent, against 56 percent in the controls. Follow-up came nearly two years after treatment started, so neither had settled with time.

  Leung and colleagues, The Journal of Rheumatology, 2025

• One survey asked 197 patients what they did for their illness besides taking drugs, and 41.1 percent of them did something. Just 17.8 percent of those patients exercised at all. Some 25.4 percent had been told to do specific exercises, most of them by a physiotherapist rather than a doctor.

  Weddell and colleagues, Rheumatology International, 2021

The one guideline that says exercise outright

Across all the illnesses covered here, polymyalgia rheumatica is the only one whose main society guidelines tell you outright to exercise. The European and American document says it, and so does the British one. Both back an exercise program to help hold onto muscle, to help hold onto function, and to cut the risk of falls. They stress it most for frail patients and for older patients on long corticosteroid courses.

What neither of them does is say what that program consists of, in dose, type, frequency, or intensity. That blank isn't an oversight so much as an absence. No exercise trial in this illness exists to base a figure on, so there's nothing to quote.

One paper describes the position without softening it at all. The international guidelines back patient education and exercises built for each person, and they lack the evidence behind them. What physiotherapists do for this illness hasn't been studied either, and the rest of this page is about why the recommendation is worth acting on even so.

You lose strength while the disease looks controlled

One study followed people with polymyalgia rheumatica for 18 months against matched controls, and the patients scored worse on a disability form at both visits. The differences came out at 0.33 at the start and 0.41 at follow-up. Women with the illness slowed down more when walking than female controls, by 0.13 meters per second, and they were 3.27 seconds slower getting out of a chair at follow-up. Body composition was the one thing that didn't differ, and it changed no differently over the 18 months.

Frailty is the figure that brings you up short. At the first visit, 71.2 percent of patients were heading toward frailty, against 34.4 percent in the controls, which is an odds ratio of 4.7. At follow-up it was still 60.7 percent, so the pain answering to treatment and your strength coming back are two separate events. Corticosteroids usually settle the first fast, and nothing about that guarantees the second.

That doesn't get mentioned to people up front. The story most patients hear is that corticosteroids control the pain fast, which they usually do, and the unspoken part is that everything else follows. These numbers say something different, because for a large share of people your strength doesn't come back on its own, so it's worth working on deliberately.

Tiredness and sleep, which last longer than anyone warns

A companion study measured tiredness and sleep in those patients. Bad tiredness hit 36 percent at the start and 35 percent at follow-up, against 3 percent in the controls. Poor sleep hit 77 percent at the start and 84 percent at follow-up, against 56 percent in the controls. Both were still there nearly two years after treatment began.

Bad tiredness was associated with a longer list than disease activity alone, because it was also associated with more weight and more body fat. It correlated with worry and low mood, and it correlated with disease activity, the blood markers, pain, and stiffness. That counts in practice, because if you read lasting tiredness as proof of uncontrolled swelling, you get corticosteroid decisions that touch almost nothing on that list.

What has never been tested is whether exercise changes any of it. There's no trial of exercise in this illness at all, so there's no figure to give you for tiredness or for sleep. Trying it is reasonable on the general case for staying active, and being told it's proven for this illness would be false.

What people are doing, and what they get offered

One survey asked 197 patients what they did besides taking drugs, and 41.1 percent of them did something, while only 17.8 percent exercised. A quarter had been told to do exercises for their illness. Most often a physiotherapist told them, and less often it was a family doctor or a hospital doctor. Among those who changed their exercise, about 85 percent found that it helped.

That survey also reported its limit honestly, because in its own data no single non-drug therapy correlated with better long-term outcomes. Feeling helped and being measurably better are two different things, and a survey taken at one moment in time can't tell them apart. What it does settle is that most people with this diagnosis are offered nothing at all.

Bones, corticosteroids, and what the guideline says

Anyone on a long corticosteroid course falls under the 2017 American College of Rheumatology guideline. It gives strong advice at every age, starting with calcium and vitamin D and going on to say how to change how you live. That means weight-bearing and strength-building exercise, stopping smoking, and drinking less. It's the most specific exercise wording that reaches this illness, and it comes through the drug rather than the diagnosis.

The link between corticosteroid dose and bone density is less simple than people make out. One study measured 198 patients with polymyalgia rheumatica, giant cell arteritis, and other kinds of vasculitis, and their dose didn't correlate with their lowest bone score. Neither the current dose nor the total correlated with it, though three other things correlated with lower density. Those were being lighter, having broken a bone in the spine before, and taking a heartburn drug, and not one of the three is the number most people worry about.

Read the design before you take that anywhere. That study looked at people already on treatment, most already on bone protection, at one moment in time, so it can't show what a trial would. Read carefully, it argues for bone protection and for weight-bearing work, not against them. What it does argue against is assuming that the dose alone tells you your risk.

Common misconceptions.

Cautions specific to this condition.

• Get a new headache, jaw pain when you chew, or any change in your vision seen urgently. Don't wait for a routine visit. Giant cell arteritis comes with this illness, and it can cost your sight.
• Ask about your risk of falling. Walking speed and chair-stand time both dropped faster here than in people of that age without the illness.
• Expect the guideline to tell you to exercise without saying how. So ask for a physiotherapy referral if you want one. In one survey only a quarter of patients had ever been given specific exercises.
• The 2017 corticosteroid guideline asks for weight-bearing and strength work in anyone on a long course. Those are its own words. Your team can say whether it fits you.
• Raise lasting tiredness. Don't put up with it. It hit a third of patients two years in, and it correlates with sleep, mood, and weight as well as with disease activity.
• Treat a corticosteroid step-down as a time for more attention to strength, not less. That's when weakness from the drug and weakness from not moving both appear.

Questions patients ask.